Healthcare Services

Pharmaceutical Companies Enhancing Acute Myeloid Leukemia Treatment Armamentarium With Quizartinib Approval Is Affecting The Direction Of The Acute Myeloid Leukemia Market

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Acute Myeloid Leukemia Market During 2026–2030?

The acute myeloid leukemia market has seen significant expansion in recent years. Its value is set to increase from $3.73 billion in 2025 to $3.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historic period’s growth is largely due to factors such as the rising prevalence of AML, the development of hospital infrastructure, greater awareness regarding leukemia treatments, the continued use of conventional chemotherapy protocols, and advancements in supportive care measures.

The acute myeloid leukemia market is projected to demonstrate significant expansion in the upcoming years. It is expected to grow to $5.25 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.3%. This expansion during the forecast period can be attributed to progress in targeted therapy drugs, an increase in stem cell transplant procedures, the creation of novel tyrosine kinase inhibitors, the growth of ambulatory care centers, and the incorporation of personalized medicine approaches in treatment. Major developments anticipated in the forecast timeframe include the wider adoption of targeted AML therapies, an increasing use of stem cell transplantation procedures, a rising demand for personalized chemotherapy regimens, the expanded availability of tyrosine kinase inhibitors and monoclonal antibodies, and an intensified focus on early diagnosis and AML monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp

What Influential Factors Are Boosting The Acute Myeloid Leukemia Market Demand?

The acute myeloid leukemia market is projected to expand due to the rising implementation of personalized medicine. This cutting-edge medical and healthcare strategy takes into account distinct patient characteristics such as genetic makeup, environmental factors, and lifestyle choices. For acute myeloid leukemia (AML), personalized medicine utilizes molecular profiling to pinpoint particular genetic mutations and biomarkers specific to each patient. Such data then informs the choice of targeted therapies and customized treatment regimens, thereby enhancing treatment efficacy and reducing side effects, leading to a more individualized and exact management of AML. A notable example is provided by the Personalised Medicine Coalition, a US-based hospital and health care organization, which reported in February 2024 that the FDA sanctioned 16 novel personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the growing acceptance of personalized medicine is a significant catalyst for the acute myeloid leukemia market’s expansion.

Which Segment-Based Categories Are Covered In The Acute Myeloid Leukemia Market?

The acute myeloid leukemia market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Stem Cell Transplant, Targeted Therapy

2) By Treatment Phase: Induction Therapy, Consolidation Therapy, Maintenance Therapy, Relapsed Or Refractory Therapy

3) By End-User: Hospitals, Specialty Oncology Centers, Transplant Centers, Research and Academic Institutes

Subsegments:

1) By Chemotherapy: Cytarabine-Based Therapy, Anthracycline-Based Therapy, Hypomethylating Agents, Low-Intensity Chemotherapy, Combination Chemotherapy Regimens

2) By Stem Cell Transplant: Allogeneic Stem Cell Transplant, Autologous Stem Cell Transplant, Conditioning Regimens, Post-Transplant Maintenance Therapy

3) By Targeted Therapy: FLT3 Inhibitors, IDH1 Inhibitors, IDH2 Inhibitors, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, Other Targeted Agents

Which Trends Are Influencing The Direction Of The Acute Myeloid Leukemia Market?

Leading companies operating in the acute myeloid leukemia market are concentrating on developing advanced drug solutions, such as maintenance monotherapy, to expand their product portfolios, aiming to improve patient outcomes and address unmet medical needs. Maintenance monotherapy refers to a medical treatment approach where a single therapeutic agent is administered to a patient as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. For instance, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for quizartinib (Vanflyta) for use in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults with FLT3 internal tandem duplication (ITD)-positive status, as identified by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay has also been approved as a companion diagnostic for Vanflyta. This approval is founded on positive results from the QuANTUM-First trial, which demonstrated a statistically significant improvement in overall survival for patients receiving quizartinib compared to a placebo. Quizartinib’s recommended dosage varies during the induction, consolidation, and maintenance phases. The drug is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

Who Are The Firms Contributing To The Acute Myeloid Leukemia Market Ecosystem?

Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.

Access The Complete Acute Myeloid Leukemia Market Report:

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Which Area Represents The Largest Portion Of The Acute Myeloid Leukemia Market?

North America was the largest region in the acute myeloid leukemia market in 2025. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acute Myeloid Leukemia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=6100&type=smp

Browse Through More Reports Similar to the Global Acute Myeloid Leukemia Market 2026, By The Business Research Company

Chronic Myeloid Leukemia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Leqembi Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Chronic Myeloid Leukemia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795